Sort   by:  
 Page size 
UnknownBayogenin 3-O-cellobioside confers non-cultivar-specific defence against the rice blast fungus Pyricularia oryzae.
Not available
S-EPMC7955875 | biostudies-literature
UnknownPost-intervention Status in Patients With Refractory Myasthenia Gravis Treated With Eculizumab During REGAIN and Its Open-Label Extension.
Not available
S-EPMC7905790 | biostudies-literature
UnknownConsistent improvement with eculizumab across muscle groups in myasthenia gravis.
Not available
S-EPMC7448154 | biostudies-literature
Unknown'Minimal symptom expression' in patients with acetylcholine receptor antibody-positive refractory generalized myasthenia gravis treated with eculizumab.
Not available
S-EPMC7320935 | biostudies-literature
UnknownLong-term safety and efficacy of eculizumab in generalized myasthenia gravis.
Not available
S-EPMC6619057 | biostudies-literature
UnknownEculizumab improves fatigue in refractory generalized myasthenia gravis.
Not available
S-EPMC6620379 | biostudies-literature
UnknownCasirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
Not available
S-EPMC8830904 | biostudies-literature
UnknownConvalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial.
Not available
S-EPMC8121538 | biostudies-literature
UnknownAspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
Not available
S-EPMC8598213 | biostudies-literature
UnknownTocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
Not available
S-EPMC8084355 | biostudies-literature
Sort   by:  
 Page size